Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on BioXcel Therapeutics (NASDAQ:BTAI) with a $7 price target.
June 27, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on BioXcel Therapeutics with a $7 price target.
The reaffirmation of a Buy rating and a specific price target of $7 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100